3[1]Wikstrand J,Warnold I,Olsson G,et al.Primary prevention with metoprolol in patients with hypertension.Mortality results from the MAPHY study[J].JAMA,1988,259(13):1976-1982.
4[2]Olsson G,Tuomilehto J,Berglund G,et al.Primary prevention of sudden cardiovascular death in hypertensive patients.Mortality results from the MAPHY Study[J].Am J Hypertens,1991,4(2 Pt 1):151-158.
5[3]Olsson G,Wikstrand J,Warnold I,et al.Metoprolol-induced reduction in postinfarction mortality:pooled results from five double-blind randomized trials[J].Eur Heart J,1992,13(1):28-32.
6[4]Sandberg A,Ragnarsson G,Jonsson UE,et al.Design of a new multiple-unit controlled-release formulation of metoprolol-metoprolol CR[J].Eur J Clin Pharmacol,1988,33(Suppl):S3-7.
8[6]Wieselgren I,Lundborg P,Sandberg A,et al.Pharmacokinetic and pharmacodynamic evaluation of metoprolol controlled release (CR/ZOK)50 mg in young subjects[J].J Clin Pharmacol,1990,30(2 Suppl):S28-32.
9[7]Sandberg A,Blomqvist I,Jonsson UE,et al.Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol:a comparison with conventional tablets[J].Eur J Clin Pharmacol,1988,33(Suppl):S9-14.
10[8]Lucker P,Moore G,Wieselgren I,et al.Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses[J].J Clin Pharmaeol,1990,30(2 Suppl):S17-27.
